Findings

What do systematic reviews say?

329 questions · 345 findings · 49 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 23 · 6.7%GRADE not reported 17 · 4.9%Very low 117 · 33.9%Low 87 · 25.2%Moderate 91 · 26.4%High 10 · 2.9%

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical antipsychotics vs placebo (only short term)

Weight gain (equal or greater then 7% of baseline) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
High

Atypical antipsychotics vs placebo (only short term)

High prolactin at any time during treatment · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
High

Atypical antipsychotics vs placebo (only short term)

Change in corrected QT · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
High

Atypical vs typical antipsychotics (only short term)

Worse or no improvement · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Low

Atypical vs typical antipsychotics (only short term)

Adverse effects ‐ anticholinergic effects · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Atypical vs typical antipsychotics (only short term)

Drop in the absolute neutrophil count below 1500 per mm3 · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical vs typical antipsychotics (only short term)

Adverse effects: Leaving the study early · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Moderate

Atypical vs atypical antipsychotics (only short term)

No improvement (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Moderate

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

2 findings from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.3 [0.93, 1.83]
2 studies · 461 participants
Moderate
Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.04 [0.76, 1.43]
1 study · 459 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 2.33 [1.4, 3.86]
1 study · 70 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.32 [1.06, 1.64]
2 studies · 172 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.07 [0.92, 1.25]
2 studies · 257 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.44 [0.32, 0.6]
1 study · 124 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.81 [0.37, 1.75]
2 studies · 173 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.45 [0.24, 0.84]
2 studies · 262 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with ultra low dose (<2 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.77 [0.55, 1.08]
2 studies · 461 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.78 [0.58, 1.06]
2 studies · 496 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.74 [0.54, 1]
1 study · 677 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.74 [0.34, 1.58]
1 study · 39 participants
Moderate